CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0624 (clinicaltrials.gov NCT No: NCT01985477)
Title:Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:ATRA; Dexamethasone; Revlimid
Study Status:Open
Study Description:The goal of the Phase I portion of this clinical research study is to find the
highest
tolerated dose of the combination of lenalidomide, all-trans retinoic acid
(ATRA), and dexamethasone that can be given to patients with relapsed or
refractory MM.

The goal of the Phase II portion of this study is to learn if ATRA when given
in combination with lenalidomide alone or with lenolidamide and dexamethasone
can help to control MM.

The safety of the drug combination will be studied in both phases.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:ATRA
Dexamethasone
Revlimid
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene Corporation
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults